TB researchers will test a new Bayer antibiotic

Article Abstract:

Tuberculosis, one of the most fatal illnesses in poverty stricken areas of the world is being given a new cure. Tuberculosis researchers partnering with Bayer AG are conducting clinical trials of a new antibiotic that could half treatment time.

Germany, Antibiotics, Bayer AG, Tuberculosis, BAYZY

---

Small firms seek to profit from drug giants' castoffs

Article Abstract:

Led by biochemists like Speedel Holding AG's Alice Huxley, s mall pharmaceutical companies are developing drugs that larger companies like Novartis AG had decided weren't financially viable.

Product development, Switzerland, Pharmaceutical Preparation Manufacturing, Executive changes & profiles, Blood Pressure Preparations, Officials and employees, Novartis AG, Antihypertensive drugs, Antihypertensive agents, NVTSY, Speedel, Huxley, Alice

---

Cancer drug Gleevec is shown to carry heart risk

Article Abstract:

The leukemia fighting drug, Gleevec, has been shown in a significant study to in some cases cause heart failure. The finding may be a stumbling block to the blockbuster cancer drug.

Complications and side effects, Leukemia, Gleevec (Medication)

Similar abstracts:

• Abstracts: Classic beamer's special winch control. Star is first cat of her kind. New aids in design software
• Abstracts: Breast-cancer drug wins FDA approval. Merck cervical-cancer vaccine cleared for use in girls, women. Glaxo seeks approval for drug
• Abstracts: Aeroports de Paris listing to raise up to $1.79 billion. EADS nears end to turmoil. Airports operator spreads its wings
• Abstracts: Philips net rises on asset sales; chip results sag. Philips net rises, though dollar weighs on sales. Philips earnings rise sharply, lifted by sale of chip-firm stake

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.